Gemin X Biotechnologies Inc. Announces Publication of Preclinical Data of GX15-070 in Multiple Myeloma in Blood
3/7/2007 12:04:36 PM
MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Gemin X announced today that a report published in the online version of the journal Blood demonstrated that its lead compound, GX15-070 (obatoclax), induced potent cytotoxic responses against patient-derived multiple myeloma tumor cells as a single-agent, and enhanced anti-myeloma effects when used as a combination therapy. GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.
comments powered by